Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Hansen Medical v. Luna Innovations

This article was originally published in The Gray Sheet

Executive Summary

Firms ink settlement agreement calling for Luna to give Hansen 9.9% of the company in stock, plus $5 million over four years, to resolve allegations of misappropriation of trade secrets, Luna announces Dec. 11. The pact also includes a multi-year development and supply agreement to integrate Luna's fiber optic shape-sensing technology into Hansen's medical robotic instruments. Luna simultaneously announced it has filed an amended Chapter 11 bankruptcy reorganization plan for court approval. Hansen's charges, originally filed in June 2007 in Santa Clara, Calif., Superior Court, stemmed from a previous agreement under which Luna "conducted certain research and performed certain services" for Hansen, Luna explains in its annual report. In addition to trade secret misappropriation, the allegations included aiding and abetting breach of fiduciary duty, unfair competition, breach of contract, intentional interference with contract, breach of implied covenant of good faith and fair dealing, declaratory judgment, and fraud. Last April, a jury ruled in Hansen's favor to the tune of $36.3 million

You may also be interested in...

Good News For Immunomedics' Triple Negative Breast Cancer Trial

A Phase III trial testing the antibody-drug conjugate sacituzumab govitecan was stopped early for efficacy, boding well for the BLA pending at the US FDA.

Takeda, CSL, Other Blood Plasma Firms Team On Hyperimmune COVID-19 Therapy

Deal Snapshot: Six companies seek to collect convalescent plasma from COVID-19 survivors to quickly develop hyperimmune immunoglobulin therapy for serious complications of the virus.

US FDA Requests Frequent Updates On Supply Chain Disruptions In COVID-19 Era

Pharmaceutical companies struggling to keep up with coronavirus-related supply chain havoc asked to keep the US regulator informed as situation unfolds.





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts